Asymchem Laboratories (06821) repurchased and canceled 117,500 restricted A shares.
Kailin Pharmaceutical (06821) announced that, as of the date of this announcement, it has completed the repurchase and cancellation of a total of 117,500 restricted A-shares held by 11 departed incentive recipients granted under the 2025 A-share plan, as well as those reserved for four departed incentive recipients. The company's issued share capital has remained at 361 million shares (including 333 million A-shares and 27.8345 million H-shares).
Asymchem Laboratories (06821) announced that, as of the date of this announcement, it has completed the repurchase and cancellation of a total of 117,500 restricted A-shares held by 11 incentive recipients who have left the company, including shares granted under the 2025 A-share plan and those reserved for four former incentive recipients under the same plan. The total issued share capital of the company has been reduced from 361 million shares (including 333 million A-shares and 27.8345 million H-shares) to 361 million shares (including 333 million A-shares and 27.8345 million H-shares).
Related Articles

Zhuzhou CRRC Times Electric (03898) will distribute a mid-term dividend of HKD 0.53168 per share on October 16.

TRADEGO (08017) spent HKD 830,100 to repurchase 688,000 shares on August 19.
.png)
XXF (02473) entered into a sale-leaseback agreement.
Zhuzhou CRRC Times Electric (03898) will distribute a mid-term dividend of HKD 0.53168 per share on October 16.

TRADEGO (08017) spent HKD 830,100 to repurchase 688,000 shares on August 19.

XXF (02473) entered into a sale-leaseback agreement.
.png)
RECOMMEND





